1 October 2026

Oxford BioDynamics Plc

("OBD" or the "Company")

Extension of Timetable in relation to Placing

Related Party Transaction

Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, announced on 10 August 2026 that it had conditionally raised £9.15m through a placing of 9,150,000,000 new ordinary shares (the “Placing Shares”) at a price of £0.001 per Placing Share (the “Placing”).  The Placing was approved at a shareholder meeting on 26 August 2026 and the Placing Shares were admitted to trading on AIM on 27 August 2026.

The proceeds of the Placing were received by the Company at the time of Admission, in accordance with the terms of the Placing Agreement, save for £250,000 which has yet to be received from Vulpes Investment Management (“Vulpes”).  As announced on 10 August 2026, funds managed by Vulpes, including Vulpes Life Sciences Fund, had agreed to subscribe for 500,000,000 Placing Shares for a total consideration of £500,000.  To date £250,000 has been received, with a further £250,000 yet to be paid. Vulpes, who have been a longstanding and supportive investor in the Company for several years, have informed the Company that they will settle the balance of their contractual commitment under the Placing shortly.

Accordingly, the Company, Singer Capital Markets and Merlin Partners LLP, who are parties to the Placing Agreement, have, at the request of Vulpes, today agreed to extend the time period under the Placing Agreement for payment to 30 October 2026.

The Company confirms that it is has received the entire net proceeds of the Placing, save for the £250,000 referred to above, and that this matter will not impact upon the Company’s financial position or prospects.  The Company expects to receive the remaining funds on or before 30 October 2026.

Related Party Transaction

Martin Diggle, a non-executive director of the Company, is the co-founder of Vulpes and is Chairman and a director of the Vulpes Life Sciences Fund. Excluding the 250,000,000 Placing Shares that have not yet been paid for in accordance with the terms of the Placing, Vulpes has an interest over 868,542,844 Ordinary Shares, representing 6.46% of the Company’s issued share capital as at the date of this announcement. 

The agreement with Vulpes pursuant to which the parties to the Placing Agreement have agreed to extend the time period under the terms of the Placing Agreement is considered to be a 'related party' transaction pursuant to Rule 13 of the AIM Rules.

The Directors of the Company who did not participate in the Placing (being Dr David Holbrook and Peter Presland), having consulted with the Company's nominated adviser, Singer Capital Markets Advisory, consider the amendment to the terms of the Placing Agreement to be fair and reasonable insofar as Shareholders are concerned.

Martin Diggle’s interests in the Company are amended from the statement made on 10 August 2026 and are as set out below:

1 Martin Diggle’s beneficial holding is held through the Vulpes Life Sciences Fund and Vulpes Testudo Fund, which are controlled by him.

Capitalised terms used but not otherwise defined in this announcement have the meanings set out in the Circular published on 10 August 2026.

For further information please contact:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD), the 3D Genomics Company, is an international biotechnology company, advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners.

Currently OBD has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

The Company's recently launched proprietary AI predictive platform, EpiSwitch® Orion, makes the Company's knowledgebase and analytical tools available to researchers and partners, allowing them to generate insights into 3D regulatory biology from existing datasets. EpiSwitch Orion is a cloud-based 3D genomics platform that enables pharmaceutical partners to transform standard sequencing data - including legacy whole genome datasets - into actionable discovery insights in hours rather than months. By revealing the genome's 3D architecture, EpiSwitch Orion illuminates the 90-95% of disease-associated variants in non-coding regions that traditional NGS and GWAS approaches cannot decipher, bridging the gap between statistical associations and druggable therapeutic targets. The platform is supported by the world's largest curated 3D genomics knowledgebase, featuring over 1.5 billion data points and 15 million high-confidence genomic connections validated across 18,000+ patient samples in more than 40 diseases - a foundation built over nearly two decades that enables partners to identify targets, build predictive classifier models, and design precision interventions at unprecedented speed.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

Since inception, the Company has participated in more than 40 collaborations with pharmaceutical and academic partners, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma America, and has been awarded funding through the US Foundation for the National Institutes of Health's Partnership for Accelerating Cancer Therapies programme and the EU-funded HIPPOCRATES consortium in psoriatic arthritis.

The Company's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com , X (@OxBioDynamics) or LinkedIn.